Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Опыт применения Авастина (бевацизумаба) в сочетании с химиотерапией в лечении распространенных форм немелкоклеточного рака легкого в отделении торакальной онкологии
Опыт применения Авастина (бевацизумаба) в сочетании с химиотерапией в лечении распространенных форм немелкоклеточного рака легкого в отделении торакальной онкологии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). Под редакцией В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М., 2010.
2. Molina JR et al. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc 2008; 83 (5): 584–4.
3. Shiller JH et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2002; 346: 92–8.
4. Bonomi P et al. Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000; 18: 623–31.
5. Sandler A., Bevacizumab in Non-Small Cell Lung Cancer. Clin Cancer Res 2007; 13 (15 Suppl.): 4613–6.
6. Avastin Summary of Product Characteristics.
7. Reck M, Gatzemeier U. Advanced non-small cell lung cancer therapy: historical and future perspectives. Targ Oncol 2008; 3: 135–47.
8. Reck M. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL. J Clin Oncol 2008; 27: 1227–34.
9. Crino L et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. The Lancet Oncology 2010; 11 (8): 733–40.
10. Edelman MJ. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Expert Rev. Anticancer Ther. 2001; 1 (2): 229–35.
11. Depierre A, Milleron B, Moro D et al. Phase III trial of neoadjuvant chemotherapy in resectable stage I (except T1N0), II, IIIA non-small cell lung cancer: The French experience. Proc Am Soc Clin Oncol (Abstr 1747) 1999; 18: 465a.
12. Depierre A, Milleron B, Chevret S. French Phase IIII trial of preoperative chemotherapy in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer. Lung Cancer 2000; 29 (Supp1.): 91.
13. Depierre A et al. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), I I , and IIIa Non–Small-Cell Lung Cancer JCO 2002; 20 (1): 247–53.
14. Faoro L et al. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010; (suppl. abstr. 7583) 28: 15s.
2. Molina JR et al. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc 2008; 83 (5): 584–4.
3. Shiller JH et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2002; 346: 92–8.
4. Bonomi P et al. Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000; 18: 623–31.
5. Sandler A., Bevacizumab in Non-Small Cell Lung Cancer. Clin Cancer Res 2007; 13 (15 Suppl.): 4613–6.
6. Avastin Summary of Product Characteristics.
7. Reck M, Gatzemeier U. Advanced non-small cell lung cancer therapy: historical and future perspectives. Targ Oncol 2008; 3: 135–47.
8. Reck M. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL. J Clin Oncol 2008; 27: 1227–34.
9. Crino L et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. The Lancet Oncology 2010; 11 (8): 733–40.
10. Edelman MJ. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Expert Rev. Anticancer Ther. 2001; 1 (2): 229–35.
11. Depierre A, Milleron B, Moro D et al. Phase III trial of neoadjuvant chemotherapy in resectable stage I (except T1N0), II, IIIA non-small cell lung cancer: The French experience. Proc Am Soc Clin Oncol (Abstr 1747) 1999; 18: 465a.
12. Depierre A, Milleron B, Chevret S. French Phase IIII trial of preoperative chemotherapy in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer. Lung Cancer 2000; 29 (Supp1.): 91.
13. Depierre A et al. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), I I , and IIIa Non–Small-Cell Lung Cancer JCO 2002; 20 (1): 247–53.
14. Faoro L et al. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010; (suppl. abstr. 7583) 28: 15s.
Авторы
С.В.Орлов, Л.В.Стельмах, А.М.Ложкина, А.Н.Полторацкий
СПбГМУ им. И.П.Павлова, НИИ пульмонологии
СПбГМУ им. И.П.Павлова, НИИ пульмонологии
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.